Literature DB >> 35410495

Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population.

Ganesh B Chand1, Pankhuri Singhal1, Dominic B Dwyer1, Junhao Wen1, Guray Erus1, Jimit Doshi1, Dhivya Srinivasan1, Elizabeth Mamourian1, Erdem Varol1, Aristeidis Sotiras1, Gyujoon Hwang1, Paola Dazzan1, Rene S Kahn1, Hugo G Schnack1, Marcus V Zanetti1, Eva Meisenzahl1, Geraldo F Busatto1, Benedicto Crespo-Facorro1, Christos Pantelis1, Stephen J Wood1, Chuanjun Zhuo1, Russell T Shinohara1, Haochang Shou1, Yong Fan1, Nikolaos Koutsouleris1, Antonia N Kaczkurkin1, Tyler M Moore1, Anurag Verma1, Monica E Calkins1, Raquel E Gur1, Ruben C Gur1, Marylyn D Ritchie1, Theodore D Satterthwaite1, Daniel H Wolf1, Christos Davatzikos1.   

Abstract

OBJECTIVE: The prevalence and significance of schizophrenia-related phenotypes at the population level is debated in the literature. Here, the authors assessed whether two recently reported neuroanatomical signatures of schizophrenia-signature 1, with widespread reduction of gray matter volume, and signature 2, with increased striatal volume-could be replicated in an independent schizophrenia sample, and investigated whether expression of these signatures can be detected at the population level and how they relate to cognition, psychosis spectrum symptoms, and schizophrenia genetic risk.
METHODS: This cross-sectional study used an independent schizophrenia-control sample (N=347; ages 16-57 years) for replication of imaging signatures, and then examined two independent population-level data sets: typically developing youths and youths with psychosis spectrum symptoms in the Philadelphia Neurodevelopmental Cohort (N=359; ages 16-23 years) and adults in the UK Biobank study (N=836; ages 44-50 years). The authors quantified signature expression using support-vector machine learning and compared cognition, psychopathology, and polygenic risk between signatures.
RESULTS: Two neuroanatomical signatures of schizophrenia were replicated. Signature 1 but not signature 2 was significantly more common in youths with psychosis spectrum symptoms than in typically developing youths, whereas signature 2 frequency was similar in the two groups. In both youths and adults, signature 1 was associated with worse cognitive performance than signature 2. Compared with adults with neither signature, adults expressing signature 1 had elevated schizophrenia polygenic risk scores, but this was not seen for signature 2.
CONCLUSIONS: The authors successfully replicated two neuroanatomical signatures of schizophrenia and describe their prevalence in population-based samples of youths and adults. They further demonstrated distinct relationships of these signatures with psychosis symptoms, cognition, and genetic risk, potentially reflecting underlying neurobiological vulnerability.

Entities:  

Keywords:  Genetics/Genomics; Machine Learning; Neuroanatomy; Neuroimaging; Polygenic Risk Scores; Schizophrenia Spectrum and Other Psychotic Disorders

Mesh:

Year:  2022        PMID: 35410495      PMCID: PMC9444886          DOI: 10.1176/appi.ajp.21070686

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   19.242


  37 in total

Review 1.  Schizotaxia: current status and future directions.

Authors:  Ming T Tsuang; William S Stone; Franziska Gamma; Stephen V Faraone
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

2.  Trail Making Test A and B: normative data stratified by age and education.

Authors:  Tom N Tombaugh
Journal:  Arch Clin Neuropsychol       Date:  2004-03       Impact factor: 2.813

3.  Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk.

Authors:  Dag Alnæs; Tobias Kaufmann; Dennis van der Meer; Aldo Córdova-Palomera; Jaroslav Rokicki; Torgeir Moberget; Francesco Bettella; Ingrid Agartz; Deanna M Barch; Alessandro Bertolino; Christine L Brandt; Simon Cervenka; Srdjan Djurovic; Nhat Trung Doan; Sarah Eisenacher; Helena Fatouros-Bergman; Lena Flyckt; Annabella Di Giorgio; Beathe Haatveit; Erik G Jönsson; Peter Kirsch; Martina J Lund; Andreas Meyer-Lindenberg; Giulio Pergola; Emanuel Schwarz; Olav B Smeland; Tiziana Quarto; Mathias Zink; Ole A Andreassen; Lars T Westlye
Journal:  JAMA Psychiatry       Date:  2019-07-01       Impact factor: 21.596

4.  MIDAS: Regionally linear multivariate discriminative statistical mapping.

Authors:  Erdem Varol; Aristeidis Sotiras; Christos Davatzikos
Journal:  Neuroimage       Date:  2018-03-07       Impact factor: 6.556

5.  The psychosis spectrum in a young U.S. community sample: findings from the Philadelphia Neurodevelopmental Cohort.

Authors:  Monica E Calkins; Tyler M Moore; Kathleen R Merikangas; Marcy Burstein; Theodore D Satterthwaite; Warren B Bilker; Kosha Ruparel; Rosetta Chiavacci; Daniel H Wolf; Frank Mentch; Haijun Qiu; John J Connolly; Patrick A Sleiman; Hakon Hakonarson; Ruben C Gur; Raquel E Gur
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

6.  Hippocampal and orbital inferior frontal gray matter volume abnormalities and cognitive deficit in treatment-naive, first-episode patients with schizophrenia.

Authors:  Xiaofeng Guo; Jun Li; Juan Wang; Xiaoduo Fan; Maorong Hu; Yidong Shen; Huafu Chen; Jingping Zhao
Journal:  Schizophr Res       Date:  2014-01-15       Impact factor: 4.939

7.  Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?

Authors:  S Kapur; A G Phillips; T R Insel
Journal:  Mol Psychiatry       Date:  2012-08-07       Impact factor: 15.992

8.  Multimodal population brain imaging in the UK Biobank prospective epidemiological study.

Authors:  Karla L Miller; Fidel Alfaro-Almagro; Neal K Bangerter; David L Thomas; Essa Yacoub; Junqian Xu; Andreas J Bartsch; Saad Jbabdi; Stamatios N Sotiropoulos; Jesper L R Andersson; Ludovica Griffanti; Gwenaëlle Douaud; Thomas W Okell; Peter Weale; Iulius Dragonu; Steve Garratt; Sarah Hudson; Rory Collins; Mark Jenkinson; Paul M Matthews; Stephen M Smith
Journal:  Nat Neurosci       Date:  2016-09-19       Impact factor: 24.884

Review 9.  Neuroimaging Heterogeneity in Psychosis: Neurobiological Underpinnings and Opportunities for Prognostic and Therapeutic Innovation.

Authors:  Aristotle N Voineskos; Grace R Jacobs; Stephanie H Ameis
Journal:  Biol Psychiatry       Date:  2019-09-17       Impact factor: 13.382

10.  Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study.

Authors:  Stanley Zammit; Daphne Kounali; Mary Cannon; Anthony S David; David Gunnell; Jon Heron; Peter B Jones; Shôn Lewis; Sarah Sullivan; Dieter Wolke; Glyn Lewis
Journal:  Am J Psychiatry       Date:  2013-07       Impact factor: 18.112

View more
  3 in total

1.  Two distinct subtypes of obsessive compulsive disorder revealed by heterogeneity through discriminative analysis.

Authors:  Shaoqiang Han; Yinhuan Xu; Hui-Rong Guo; Keke Fang; Yarui Wei; Liang Liu; Junying Cheng; Yong Zhang; Jingliang Cheng
Journal:  Hum Brain Mapp       Date:  2022-04-05       Impact factor: 5.399

2.  Immune-Related Genomic Schizophrenic Subtyping Identified in DLPFC Transcriptome.

Authors:  Eva Childers; Elijah F W Bowen; C Harker Rhodes; Richard Granger
Journal:  Genes (Basel)       Date:  2022-07-04       Impact factor: 4.141

3.  Abnormal regional homogeneity in right caudate as a potential neuroimaging biomarker for mild cognitive impairment: A resting-state fMRI study and support vector machine analysis.

Authors:  Yujun Gao; Xinfu Zhao; JiChao Huang; Sanwang Wang; Xuan Chen; Mingzhe Li; Fengjiao Sun; Gaohua Wang; Yi Zhong
Journal:  Front Aging Neurosci       Date:  2022-09-01       Impact factor: 5.702

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.